Abstract: Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.
Abstract: The invention concerns compounds of formula (I), wherein each of G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula: NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3 together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene, and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.
Type:
Grant
Filed:
March 26, 1997
Date of Patent:
October 12, 1999
Assignee:
Zeneca Limited
Inventors:
Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston
Abstract: Disclosed are an electroless copper plating solution comprising a copper ion, a copper ion-complexing agent, a reducing agent and a pH-adjusting agent, the plating solution comprising a trialkanolmonoamine or a salt thereof as a complexing agent and accelerator in an amount giving a higher copper deposition speed than the copper deposition speed obtained when the trialkanolmonoamine or salt thereof is present in an amount sufficient to complex the copper ion but not enough to function as the accelerator, and 1.2.times.10.sup.-4 to 1.2.times.10.sup.-3 mole/l of an iron ion compound as a reaction initiator and/or 1.92.times.10.sup.-4 to 1.92.times.10.sup.
Abstract: Novel strains of the insecticidal microorganism Bacillus thuringiensis are described. These contain novel genes, and in particular a gene coding for a novel insecticidal endotoxin, 81 kiloDaltons in length, toxic to both Lepidoptera and Coleoptera. The novel strains and the genes they contain may be used to combat insect attack against plants.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
October 12, 1999
Inventors:
Robert G Blenk, Susan Ely, Ravindra Haribhai Tailor, Janet Mary Tippett
Abstract: A semiconductor device having a closed step portion and a global step portion including an insulating layer having a planarized surface on the global step portion is provided. A dummy pattern is formed by forming an insulating layer on the global step portion and then patterning through a photolithography process. After forming the dummy pattern for compensating steps in the global step portion and between the closed step portion and the global step portion, a BPSG layer is formed on both the closed step portion and the global step portion, and then the BPSG layer is heat-treated to cause it to reflow. The BPSG layer as an insulating interlayer having a planarized surface. The improved planarization decreases the occurrence of notching and discontinuities in the succeeding metallization processes thereby enhancing the yield and electrical characteristics of the semiconductor device.
Type:
Grant
Filed:
April 22, 1997
Date of Patent:
October 12, 1999
Assignee:
Samsung Electronics Co., Ltd.
Inventors:
Kyeong-tae Kim, Yun-seung Shin, Young-hun Park, Won-mo Park, Ji-hong Ahn
Abstract: The biosynthesis of lignin in plants is regulated by insertion into the plant genome by altering the plant's ability to synthesise the enzyme O-methyl transferase, an enzyme involved in the lignin biosynthetic pathway. Production of O-methyl-transferase may be enhanced by insertion into the plant genome by transformation of one or more additional copies of the O-methyl-transferase gene or production may be inhibited by insertion of a gene encoding anti-sense mRNA directed against the mRNA encoded by the endogenous O-methyl-transferase gene.
Type:
Grant
Filed:
October 27, 1994
Date of Patent:
September 28, 1999
Assignee:
Imperial Chemical Industries PLC
Inventors:
Bernard Jean Meinrad Fritig, Jan Van Doorsselaere, Dirk Gustaaf Inze, Lise Jouanin, Mary Elizabeth Knight, Marc van Montagu, Michel Legrand
Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalyzed reactions.
Type:
Grant
Filed:
October 22, 1997
Date of Patent:
September 28, 1999
Assignees:
Zeneca Limited, Cancer Research Campaign Technology Limited
Inventors:
Philip John Burke, Robert Ian Dowell, Anthony Brian Mauger, Caroline Joy Springer
Abstract: A motor vehicle wheel balancing machine holds a motor vehicle wheel by clamping it on a balancing machine measuring spindle. After an operation to measure the unbalance of the the wheel has been preformed, a balancing weight is attached to the wheel using a sensor, and the measuring spindle is stopped with a holding brake which is activated when the sensor is activated.
Abstract: The invention relates to quinazoline derivatives or pharceutically-acceptable salts thereof, which possess anti-tumor activity; to processes for their manufacture; and to pharmaceutical compositions containing them.The invention provides a quinazoline of the formula: ##STR1## wherein R.sup.1 is (1-4C)alkyl; the quinazoline ring may optionally bear one or two further substituents selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy;R.sup.2 is hydrogen or (1-4C)alkyl;R.sup.3 includes hydrogen and (1-4C)alkyl; andAr is optionally substituted phenylene or heterocyclene;or a pharmaceutically-acceptable salt or ester thereof.
Type:
Grant
Filed:
March 9, 1993
Date of Patent:
September 21, 1999
Assignees:
Zeneca Limited, British Technology Group Ltd.
Inventors:
Stephen John Pegg, James Michael Wardleworth
Abstract: The invention concerns 4-anilinoquinazoline derivatives of the formula I ##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy;n is 1, 2 or 3;each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo such as 2-oxo-4-imidazolin-1-yl;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
Abstract: The present invention provides a superhard film-coated member having a diamond or diamond-like carbon film strongly bonded to a cemented carbide substrate and a method of manufacturing such a member. The cemented carbide substrate is subjected to heat treatment to cause the bonding metal in a region of the substrate near to its surface to migrate to the surface so as to form hemispherical deposits thereon. The deposits are left undisturbed or a part or all thereof are removed, and subsequently diamond and/or diamond-like carbon is grown on the substrate surface by a chemical vapor deposition process. The deposits formed on the substrate surface have the effect of significantly improving the bonding strength between the superhard films and the cemented carbide substrate to allow formation of thicker film coatings.
Abstract: The invention concerns the quinazoline derivative 6-(2-methoxyethylamino)-7-methoxy-4-(3'-methylanilino)quinazoline, or a pharmaceutically-acceptable salt thereof, processes for its preparation, pharmaceutical compositions containing the compound and the use of the receptor tyrosine kinase inhibitory properties of the compound in the treatments of proliferative disease such as cancer.
Abstract: Yeast Artificial Chromosomes (YACS) containing DNA encoding the cystic fibrosis (CFTR) gene are described. The YACs allow detailed analysis of the coding and non-coding regions of the gene and the determination of cystic fibrosis alleles in sample DNA from an individual or individuals.
Type:
Grant
Filed:
May 27, 1994
Date of Patent:
August 17, 1999
Assignee:
Zeneca Limited
Inventors:
Rakesh Anand, Alexander Fred Markham, John Craig Smith, Rashida Anwar, John Hamilton Riley, Donald James Ogilvie, Paul Elvin
Abstract: The hydrocarbon light-off time in engine exhaust is reduced by employing a hydrogen oxidation catalyst, a CO oxidation catalyst of light-off temperature for CO and/or hydrogen below ambient temperature, and sufficient oxygen and sufficient CO and/or hydrogen in the exhaust that the exothermic reaction of the oxygen with the CO and/or hydrogen over the CO oxidation catalyst generates enough heat to raise the temperature of the CO oxidation catalyst to at least the light-off temperature of the hydrocarbon oxidation catalyst.
Type:
Grant
Filed:
February 4, 1997
Date of Patent:
August 17, 1999
Assignee:
Johnson Matthey PLC
Inventors:
Stephen C Bennett, Jonathan C Frost, David S Lafyatis, Andrew P Walker
Abstract: Modified polyethylene terephthalate polymers, particularly suitable for making carbonated drinks or mineral water bottles by injection (stretch) blow moulding, include a small proportion (from 0.007 to 0.08 mole %) of residues of a polyfunctional hydroxyl compound such as pentaerythritol as a chain branching agent and have (after solid phase polymerisation processing) melt viscosity values of from 300 to 1050 Pa.s (3000 to 10500 Poise) at 295.degree. C. (approximately Intrinsic Viscosity 0.6 to 0.9). The polymers also preferably include from 0.5 to 5 mole % of residues derived from a chain orientation disrupting monomer such as iso-phtalic acid. Best results are obtained in restricted ranges of polymer viscosity, hydroxyl compound and also chain orientation disrupting monomer level. As compared with conventional PET the polymers have the advantage that solid phase polymerisation rates are much improved.
Type:
Grant
Filed:
January 12, 1995
Date of Patent:
August 17, 1999
Assignee:
Imperial Chemical Industries PLC
Inventors:
Sarah Jennifer Greaves, David Anthony Harrison, Kenneth Morgan Jones
Abstract: A color cathode ray tube includes a faceplate and a phosphor screen provided on the inner surface of the faceplate and including red, green, and blue phosphor layers. A color filter layer is interposed between the inner surface of the faceplate and the phosphor screen. The color filter layer includes color filters opposed individually to the phosphor layers of the phosphor screen and having colors corresponding thereto. Color filters of each color have a higher transmittance for light beams with wavelengths which are in a range of .+-.20 nm of the maximum emission spectrum wavelength of the phosphor layers of the corresponding color than for light beams with wavelengths which are outside the range and which are between 400 nm and 650 nm.
Abstract: The invention relates to a cosmetic composition containing, in a cosmetically acceptable aqueous medium, at least one non-ionic surfactant of the alkylpolyglycoside family and/or a polyglycerol non-ionic surfactant, and at least one sequenced polydimethylsiloxane/polyoxyalkylene copolymer, as well as a process of cosmetic treatment consisting in applying a cosmetically effective quantity of this composition to keratinic materials.
Abstract: The invention concerns quinazoline derivatives of formula wherein n is 1, 2 or 3 and each R.sup.2 is independently halogeno; and R.sup.1 is di-?(1-4C)alkyl!amino-(2-4C)alkoxy, pryolidin-1-yl-(2-4C)alkoxy,piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy or 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkoxy; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
Abstract: Novel biologically-active 3-substituted trioxanes of the formula ##STR1## wherein R represents a substituted alkyl or aryl group of 1-20, preferably 1-12, carbon atoms, and methods for the use of biologically-active 3-substituted trioxanes of this formula as antiparasitic agents, particularly for the treatment of malaria.
Type:
Grant
Filed:
December 2, 1996
Date of Patent:
August 3, 1999
Assignee:
Johns Hopkins University
Inventors:
Gary H. Posner, Jared N. Cumming, Soon Hyung Woo
Abstract: A method and device for controlling a CPU stop clock interrupt of a computer system. The device includes an idle detector and a control processor. A CPU having a stop clock interrupt mode receives a stop clock interrupt signal and sets up and clears the stop clock interrupt mode according to a logic state of the stop clock interrupt signal. The control processor receives a signal representing an idle condition of the computer system from the idle detector, a signal for enabling idle detector control of the CPU stop clock interrupt mode and a signal for forcing the CPU to resume a normal mode by clearing the stop clock interrupt mode. The idle condition can be defined by a computer user according to a selection of predetermined times during which no user inputs are received by the computer system.
Type:
Grant
Filed:
February 9, 1996
Date of Patent:
August 3, 1999
Assignee:
Samsung Electronics Co., Ltd.
Inventors:
Jung-Gyu Lim, Hee-Duck Park, Shung-Hyun Cho, Noh-Buyng Park